AGE-RELATED DECLINE IN IMMUNITY IS A DOMINANT DRIVER OF SHINGLES1-3

 

AGE

Increasing age causes a natural decline in immunity.2

IMMUNITY

As immune function declines, there is a reduction in the number and functionality of immune cells that prevent reactivation of VZV.1-6

 

SHINGLES

Age-related decline in immunity leads to a sharp increase in the incidence and complications of shingles.1,2

By age 85, the lifetime risk of shingles rises from 1:3 to 1:2.2,7

 

In older patients, achieving high vaccine efficacy rates can be challenging.3

VZV=varicella zoster virus.


NEARLY EVERYONE IS AT RISK FOR SHINGLES2,8,9

99% of people ≥50 years old are infected with the varicella zoster virus.8

In 1 out of 3 people, the dormant virus reactivates and causes shingles—a blistering rash that can be excruciatingly painful.2,9

The most feared complication of shingles is surely PHN—the prolonged, sometimes incapacitating pain that continues after resolution of the rash.12

- Centers for Disease Control and Prevention, June 2015


Indication

SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older.

SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox).

Important Safety Information

  • SHINGRIX is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX
  • Review immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions. Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX
  • Solicited local adverse reactions in subjects aged 50 years and older were pain (78.0%), redness (38.1%), and swelling (25.9%)
  • Solicited general adverse reactions in subjects aged 50 years and older were myalgia (44.7%), fatigue (44.5%), headache (37.7%), shivering (26.8%), fever (20.5%), and gastrointestinal symptoms (17.3%)
  • SHINGRIX was not studied in pregnant or lactating women, and it is unknown if it is excreted in human milk. Therefore, it cannot be established whether there is vaccine-associated risk with SHINGRIX in pregnant women or if there are effects on breastfed infants or milk production/excretion
  • Vaccination with SHINGRIX may not result in protection of all vaccine recipients

References: 1. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007; 356(13):1338-1343. 2. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-5):1-30. 3. Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494-500. 4. Chlibek R, Smetana J, Pauksens K, et al. Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: a phase II, randomized, controlled study. Vaccine. 2014;32(15):1745-1753. 5. Patterson-Bartlett J, Levin MJ, Lang N, Schödel FP, Vessey R, Weinberg A. Phenotypic and functional characterization of ex vivo T cell responses to the live attenuated herpes zoster vaccine. Vaccine. 2007;25(41):7087-7093. 6. Weinberg A, Lazar AA, Zerbe GO, et al. Influence of age and nature of primary infection on varicella—zoster virus—specific cell-mediated immune responses. J Infect Dis. 2010;201(7):1024-1030. 7. Schmader K. Herpes zoster in older adults. Clin Infect Dis. 2001;32(1):1481-1486. 8. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. 9. Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. 10. Prescribing Information for SHINGRIX. 11. Yawn BP, Saddier P, Wollan PC, St. Sauver JL, Kurland MJ, Sy LS, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341-1349. 12. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices (ACIP) Summary Report. June 24-25, 2015.

All trademarks are the property of their respective owners.

1004182R0 April 2018